Therapeutic Options for the SARS-CoV-2 Virus: Is There a Key in Herbal Medicine?

Nitin Sharma1, Giriraj T. Kulkarni2, Anant Narayan Bhatt3, Saurabh Satija4,5, Lubhan Singh6, Anjana Sharma7, Kamal Dua4, Ritu Karwasra8, Asim Ali Khan8, Nadeem Ahmad9, and Khalid Raza10

Abstract
SARS-CoV-2 has been responsible for over 500 million cumulative cases all over the world since December 2019 and has marked the third introduction of a highly pathogenic virus after SARS-CoV and MERS-CoV. This virus is in a winning situation because scientists are still racing to explore effective therapeutics, vaccines, and event treatment regimens. In view of progress in current disease management, until now none of the preventive/treatment measures can be considered entirely effective to treat SARS-CoV-2 infection. Therefore, it is required to look up substitute ways for the management of this disease. In this context, herbal medicines could be a good choice. This article emphasizes the antiviral potential of some herbal constituents which further can be a drug of choice in SARS-CoV-2 treatment. This article may be a ready reference for discovering natural lead compounds and targets in SARS-CoV-2 associated works.

Keywords
SARS-CoV-2, herbal medicine, natural product, coronavirus, pneumonia

Received: May 30th, 2022; Accepted: August 29th, 2022.

Introduction
The recent eruption of β coronavirus (CoV-19) started in early December 2019 in Wuhan city of China. A large population of pneumonic patients was identified leading to the death of thousands of patients globally caused by CoV-19. The very popular name of CoV-19 by the World Health Organization is severe acute respiratory syndrome Corona virus-2 (SARS-CoV-2).1 Till July 15th, 2022, over 565.5 million infected cases have been reported, of which, more than 6.3 million have lost their life.2 Coronavirus (CoVs) was identified for the first time in 1960 under the family Coronaviridae. Four types of CoVs have been discovered to date, among which α and β CoVs tend to circulate in mammalians and δ and γ CoVs in birds.3,4 Till now six subtypes of human vulnerable CoVs have been recognized of which two CoVs, namely HCoV-229E and HCoV-NL63, belong to α CoVs while HCoV-HKU1, HCoV-OC43, SARS-CoV, and MERS-CoV are β CoV.5 All identified human susceptible CoVs have low pathogenicity, except SARS-CoV and MERS-CoV. Several deaths were recorded due to the outbreak of SARS-CoV6 and MERS-CoV7 in 2003 and 2012, respectively. Crossing the boundaries SARS-CoV-2 has represented a pandemic risk globally.

A report stated that SARS-CoV-2 has long genomes (up to 32 kb), which are in the same β CoVs elade as bat CoV RaTG13 (96.2% genomic similarity) and SARS-CoV (79.5% genomic similarity).8 SARS-CoV-2 is a positive sense single-stranded
RNA. Several proteins, like spike (S), membrane (M), nucleocapsid (N), and envelope (E), are protected in the viral structure and characterized by their unique function. S protein is a surface protein that forms homotrimeric spikes on the virus surface which functionally regulate the binding and fusion of the virus into the host cell through their subunits S1 and S2. M and E proteins give the virus its shape and a matured viral envelope. Apart from this function, the E protein is also involved in the production of virus-like particles. Unlike other proteins, N protein is present inside the envelope and binds with RNA to make nucleocapsids. Since the beginning of the SARS-CoV-2 outbreak, numerous studies have been conducted showing potential applications for the prevention and recovery management of the disease. Herbal medicines have shown appreciable results in improving the clinical condition associated with the disease, not only by regulating the pro- and anti-inflammatory cytokines, but also by showing alleviated antiviral activities. Thus, the aim of this review article is to summarize some selected phytoconstituents which have been traditionally used to treat various infectious diseases, so that their application may be explored for the effective management of SARS-CoV-2 infection.

Mechanism of Viral Infection

SARS-CoV-2 uses its spike (S) protein to internalize with the human angiotensin-converting enzyme 2 receptor (hACE2), which is found on ciliated lung epithelia. The S proteins of the virus mediate the membrane fusion process through hACE2 to infect human cells (Figure 1). Further, the internalization of S protein and the hACE2 receptor facilitate the fusion and infection by bringing the viral and cellular membranes close. After entering the cell, the envelope of SARS-CoV-2 is removed and virus RNA is released into the cytoplasm of the host cell.

RNA of SARS-CoV-2 directly enters into the ribosome of the host cell for translation. Therefore, it can directly produce the essentially required proteins to replicate in the host cell cytoplasm. The RNA-dependent RNA polymerase (RdRp) enzyme first transcribes the negative strand which is used to translate additional proteins and replication of new positive-stranded RNA genomes for the reproduction of newer viruses. The large polyprotein translated by the host ribosome is slashed by its own proteases into multiple proteins. The nucleocapsid protein N binds with the helical RNA and enters into the lumen of the endoplasmic reticulum, where it is enveloped by lipid, spike protein S, and envelope protein E. Further, these newly formed viruses in the host cell are transported to the cell membrane through Golgi vesicles and exocytosed into extracellular space to infect new cells. This process increases the viral load in the infected individual and the infected person starts showing symptoms and becomes a carrier of the virus also. Subsequently, the person-to-person spread of infection is initiated by contact with infected individuals. It is also evident that SARS-CoV-2 may be present in the feces of infected individuals and even after the patient is cured, thereby indicating a feco-oral route of viral transmission as well.

Potential Antiviral Herbal Constituents

The application of phytoconstituents for antiviral indications is not new. Various published reports have shown the potential applications of herbal products in various diseases associated with viruses such as hepatitis, influenza, HIV, and SARS-CoV. Here, we summarize various phytoconstituents which have been explored against viral infection and further could be used for the effective management of SARS-CoV-2.

Hesperidin

Hesperidin (formerly called vitamin P, C_{22}H_{34}O_{15}) is a bioflavonoid and a by-product of various citrus fruits like sweet orange (Citrus aurantium), lemon (Citrus limon), grapefruit (Citrus ximplaria), mandarin (Citrus unshiu), and Calamansi (Citrus mitis). In addition to citrus fruits, it is also present in sufficient quantities in non-citrus fruits like prickly ash (Zanthoxylum avatarum), indigofera (Indigofera tinctoria), and peppermint (Menta piperita). Hesperidin is a glycoside composed of an aglycone (hesperetin) and a disaccharide (rutinose), thus called hesperetin 7-O-β-rutinoside. Hesperidin has been of considerable interest due to its pharmacological activities. Garg et al proved its application for treating various diseases associated with increased permeability of blood capillaries and manifested in symptoms like edema, hypertension, and bleeding. Various reports support that hesperidin reduces capillary permeation and gives symptomatic relief in such diseases, including diabetes, hemorrhoids, scurvy, ulcer, bruising, and tuberculosis. Reports also suggest its application because of its anti-lipidemic, antimicrobial, and antiviral properties. Hesperidin also regulates the levels of various inflammatory markers like interleukin (IL) and tumor necrosis factor-α (TNF-α).

Hesperidin could be a choice of phytoconstituent to treat SARS-CoV-2 infection because of its capacity in controlling capillary permeation and inhibiting various inflammatory markers (IL and TNF-α). A recent report has shown ACE2 receptor affinity of some flavonoids, including hesperidin, using molecular docking. The study implied that these flavonoids could play a potential role in SARS-CoV-2 treatment. A similar computational study inferred that hesperidin might be a 3-chymotrypsin-like protease inhibitor. Using docking methodology, an interfering mechanism of S protein with ACE2 receptor was established. Another published report confirmed the low binding energy of hesperidin with the ACE2 receptor compared to Nelfinavir and can be used against SARS-CoV-2 infection. In another study, the phytoconstituent was screened against the modeled structure of the receptor binding domain of the S protein and ACE2 receptor. The pharmacokinetic parameters of hesperidin were analyzed using various modelling software and showed good.
pharmacokinetics properties, minimal toxicity, and good bioavailability. A report of a clinical study also confirmed that the application of 1 g hesperidin daily showed a reduction of 14.5% of symptoms associated with SARS-CoV-2 infection in 216 symptomatic non-vaccinated subjects.

Quinonemethide Triterpenoids

Quinonemethide triterpenoids (QMTs) are secondary metabolites present specifically in plants belonging to the family Celastraceae, which is comprised of approximately 90 tropical and subtropical genera of shrubs and lianes. The name of this family (Celastraceae) is due to the presence of celastrol, an atripterine belonging to the quinine methides. In nature, QMTs are also considered a chemotaxonomic biomarker of the family. QMTs are the most common class of celastroloids, consisting of a quininemethide chromophore with a triterpenoid skeleton (Figure 2b).

To date, QMTs have been investigated for many therapeutic effects, such as anticancer, anti-inflammatory, and antileukemia activity. A published report demonstrated the inhibitory activity of some QMTs (celastrol, pristimerin, and tingenone isolated from *Tritergium regelii*) against SARS-CoV. Molecular docking simulation was used to investigate the interaction of QMTs with the active site of SARS-CoV and their potential effectiveness was shown by low values for docking energy. With the genomic similarity of SARS-CoV and SARS-CoV-2, QMTs may also be considered as potential therapeutic agents against SARS-CoV-2.

Emodin

Emodin [6-methyl-13,8-trihydroxyanthraquinone (Figure 2c)] is a natural anthraquinone derivative. It is isolated from different medicinal plants of Asian and European origin, namely, *Aloe vera*, Himalayan rhubarb (*Rheum australe*), buckthorn (*Rhamnus species*), rhubarb (*Rheum barbarum*, and *R. rhaponticum*),...
Japanese knotweed (*Reynoutria japonica* syn. *Polygonum cuspidatum*), and Chinese rhubarb (*Rheum palmatum*). Emodin has shown several therapeutic values including hepatoprotective, anticancer, and antimicrobial activities. Its antiviral activity against different viruses is well documented. Inhibitions of virus replication were studied on Hep-2 cells, using MTT and plaque reduction assays. Emodin exhibited potent inhibitory effects against both the selected viruses. However, it did not block the absorption of the virus into cells and could not inactivate the viruses directly. In another work, the application of emodin against coxsackievirus B4 was shown.

A recent report stated the inhibition of SARS-CoV and HCoV-OC43 by emodin. Batista et al have also proved the virucidal effect of emodin against the Zika virus. At a 40 µM concentration, emodin inhibited the infectivity by 83.3%. Li et al, in a review article, have mentioned that emodin can interfere with the replication of poliovirus.

Lycorine is a pyrrolophenanthridine alkaloid (Figure 2d) found in various Amaryllidaceae species. It was first isolated from *Narcissus pseudo-narcissus* and, therefore, initially called narcissia, but was later named lycorine. This alkaloid is reported to possess different pharmacological activities namely antiparasitic, antibacterial, anti-inflammatory, anti-tumor, and antiviral. Lycorine is reported for increasing the survival of mice infected with human enterovirus-71. The possible mode of action of lycorine is a viral replication inhibitory effect by blocking the elongation of the viral polyprotein.

Lycorine is also reported as a potent therapeutic substance against SARS-CoV and avian influenza (H5N1) virus. Guo et al demonstrated the mechanism of 32 lycorine derivatives against the hepatitis C virus. Another report also suggested that lycorine can interfere with the replication of poliovirus.

A cellular study conducted by Zhang et al, also confirmed the SARS-CoV-2 inhibitory activity of lycorine. However, only an extensive clinical study can confirm the application of lycorine in the management of the disease.

**Glycyrrhizic Acid**

Glycyrrhizic acid, obtained from liquorice root (*Glycyrrhiza glabra*), is a saponin that is also known as glycyrrhizin or glycyr rhizinic acid. This is a well-recognized phytoconstituent from ancient times used for the treatment of several viral infections. Glycyrrhizic acid is also reported to inhibit many viruses infecting the respiratory system, namely influenza A, H1N1, and SARS-associated...
Glycyrrhizic acid and its derivatives showed potential against SARS-associated CoVs when tested against two clinical isolates. The above data showed good support regarding the potential application of glycyrrhizic acid in combating COVID-19. More randomized clinical trials will be required to obtain a precise conclusion.

Betulinic Acid

Betulin, a pentacyclic triterpene, is obtained from the outer bark of Betula species, family Betulaceae (Figure 2f). Betulinic acid, which can be obtained from ethanolic and methanolic extracts of Betula species, possesses various pharmacological activities like anticancer, antibacterial, antiplasmodial, and anti-leishmanial. Various studies have suggested the inhibitory activity of betulinic acid against many viruses, such as HIV-1NL4-3 and HIV-1JRCSF. In one study, betulinic acid derivatives were used against the HIV virus. In some other studies, the compound showed significant inhibitory potential against ECHO-6 virus, and A549 cells infected with influenza A/PR/8 virus. Some analogues of betulinic acid also display anti-Human Papilloma Virus type 11 activity. A study conducted on the antiviral activity of natural products against CoVs suggested that betulinic acid may be considered active against SARS-CoV 3CL.pro. Molecular docking analysis was conducted on natural products and the study suggested that betulinic acid has the potential to inhibit the replication and 3CL.pro target of 2019-nCoV with a binding energy of 4.23. Considering the previous reports, these phytoconstituents may be future therapeutic agents against 2019-nCoV due to their additional anti-inflammatory action and significant activity against SARS-CoV.

**Lectins**

Lectins are naturally-occurring glycoproteins. Some foods with higher levels of lectins include beans, peanuts, lentils, tomatoes, potatoes, eggplants, vegetables, and wheat. Lectins protect plants during development.

**Table 1. Possible Mechanism of Action of Various Phytoconstituents as Antiviral Agents.**

| Phytoconstituents | Possible mechanism of action | Reference |
|-------------------|-----------------------------|-----------|
| Hesperidin        | Prevents SARS-CoV-2 internalization with the host cell by showing affinity to the three main protein receptors of SARS-CoV-2 (SARS-CoV-2 protease domain, the receptor binding domain of the spike glycoprotein, and the receptor binding domain of ACE2 at the protease domain) | 61 |
| Quinonemethide triterpenoids | 3C-like protease (3CL.pro) inhibitor | 30 |
| Emodin            | Inhibits the ion channel formed by the 3a protein and thus prevents virus release | 31 |
| Lycorine          | Although the exact mechanism is unclear, the antiviral effect may be due to the reproduction inhibition by hindering viral polymerase activity or extension of the viral polyprotein during protein synthesis | 47 |
| Glycyrrhizic acid | Inhibition of virus replication in the host cell. It also inhibits adsorption and penetration of the virus in the early steps of the replicative cycle | 62 |
| Betulinic acid    | 3C-like protease (3CL.pro) inhibitor | 76 |
| Lectins           | They bind with SARS surface proteins, which are heavily glycosylated, and inactivate them from binding to host cells | 79 |

**Anti-Malarialphytoremedies**

According to an international study by thousands of doctors, anti-malarial medicines are the best CoVs treatment currently
available. From 30 countries, and about 2000 doctors surveyed, 37% said that they were the most efficient virus therapy. Doctors in Europe, the USA, and China were given permission to prescribe hydroxychloroquine to SARS-CoV-2 patients when the epidemic was spiralling and there was no treatment at all. Some phytoremedies can also be looked at for the treatment of CoVs when considering the potential of anti-malarial medicines.

Artemisinin, which is obtained from Artemisia annua leaves, is perhaps the most powerful natural anti-malarial source. Artemisinin is only used in conjunction with other anti-malarial drugs consisting of Artemisinin Combination Therapy, owing to weak pharmacokinetic properties and careful attempts to curtail monotherapy resistance. In the developing world, Artemisinin involves a small return on the plant and higher costs for secondary anti-malarial drugs in Legislation. Apparently, this is the only way to treat the malaria parasites with increased drug resistance such as chloroquine and hydroxychloroquine. Data obtained from a randomized and controlled clinical study revealed the efficacy of artemisinin-piperaquine for the treatment of COVID-19, with 10.6 ± 1.1 days mean time to reach an undetectable viral RNA level for the treatment group and 19.3 ± 2.1 days for the control group.84,85

Chinese Remedies Against SARS-CoV

Some Chinese herbs are known for their antiviral effects and have, therefore, been investigated for their potential function against SARS-CoV75.85 Many studies showed that they decrease the expression of inflammatory markers and regulate the TLR7/NF-κB pathway to show antiviral effects.86 Gao et al studied the anti-inflammatory and immunoregulatory potential of Yupingfeng powder. The study showed that the formulation was effective against external pathogens such as SARS-CoV infection. Furthermore, humoral and cellular immune function in mice with immunosuppression also improved with the formulation. Another Chinese formulation, named Lianhuaqingwen capsule, is one of the most prescribed Chinese formulations to treat respiratory tract infections. This formulation effectively suppresses the inflammatory cytokines and thereby may be a promising option for controlling the influenza virus.88 A clinical trial conducted on COVID-19 infected patients revealed the effectiveness of Lianhuaqingwen by showing rapid recovery as compared to the control group.89

A large number of herbal extracts show efficiency against SARS-CoV, some of them being Lycoris radiata, Artemisia annua, Pyrusia lingua, and Lindera aggregata. Lycoris radiata extract was the most active. Bioassay-guided chromatographic separation of the extract led to the isolation of lycorine, which inhibited SARS-CoV at a concentration of 15.7 nM. Lycorine showed a high specificity index against HepG2 cell lines.90 Another work, reported by Lau and coworkers, shows the inhibition of two main SARS-CoV proteins (3CLpro and RdRp) by the aqueous extract of Houttuynia cordata. Additionally, the extract also increased the cell count of CD4+ and CD8+, indicating its immune/stimulation function.91

Recent results indicate that three alkaloids, tetrandrine, fangchinoline, and cepharanthine substantially prevent viral-induced cell death. The replication of HCoV-OC43, along with S and N protein expressions, was significantly suppressed by alkalo
dal treatment. A total of 221 phytochemicals were screened for SARS-CoV antiviral activity; 10 diterpenes, 2 sesquiterpenes, 2 triptenes, five lignans, and curcuminoids were shown to have an inhibitory activity.76

Here we have summarized some of the previously reported phytoconstituents being used as antivirals for other CoVs infections. The inhibitory mechanisms of these phytoconstituents may also be replicated for the prevention of COVID-19. However, extensive research and clinical evaluation are required to establish these phytoconstituents as effective tools against COVID-19 infection.

Conclusion

Herbal drugs have been useful in various viral infections. Many phytoconstituents have exhibited excellent antiviral properties and the mechanism of their action against different viruses has been reported. In the case of the outbreak of the COVID-19 pandemic, a situation for which there were no available drugs, and completely effective vaccines, many herbal molecules that have shown potent anti-SARS-CoV activity may find application. However, clinical studies of some phytoconstituents, such as hesperidin, emodin, artemisinin, lycorine, and lianhuaqingwen, have shown exciting anti-SARS-CoV efficacy. However, still more phytoconstituents should be studied through proper clinical trials to find more effective anti-SARS-CoV treatments.

Authors’ Contributions

NS, GTK, ANB, SS: conceptualization, data collection/curation, analysis, writing, reviewing the first draft. NS, LS, AS, KD, RK: analysis, writing the first draft. NA, KR: reviewing, editing.

Authors’ Note

Kamal Dua, Faculty of Health, Australian Research Centre in Complementary and Integrative Medicine, University of Technology Sydney, Ultimo, NSW, Australia; Uttarakhand Institute of Pharmaceutical Sciences, Uttarakhand University, Dehradun, India.

Declaration of Conflicting Interests

The authors declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

Funding

The authors received no financial support for the research, authorship, and/or publication of this article.
Ethical Approval
This study does not directly involve humans or other organisms as it is a review study.

Consent for Publication
All authors consented to submitting the manuscript to Natural Product Communications.

ORCID iDs
Khalid Raza https://orcid.org/0000-0002-3646-6828
Nitin Sharma https://orcid.org/0000-0001-6682-748X

References
1. Guo Y-R, Cao Q-D, Hong Z-S, et al. The origin, transmission and clinical therapies on coronavirus disease 2019 (COVID-19) outbreak – an update on the status. Military Med Res. 2020;7(1):11. doi:10.1186/s40779-020-00240-0
2. WHO Situation Report. https://www.who.int/docs/default-source/coronaviruse/situation-reports/20200428-sitrep-99-covid-19.pdf?sfvrsn=19fc381_2
3. Woo PCY, Lau SKP, Lam CSF, et al. Discovery of seven novel mammalian and avian coronaviruses in the genus Deltacoronavirus supports bat coronaviruses as the gene source of alphacoronavirus and betacoronavirus and avian coronaviruses as the gene source of gammacoronavirus and deltacoronavirus. J Virol. 2012;86(7):3995-4008. doi:10.1128/JVI.00540-11
4. Quazi S, Sheikh K, Faheem M, Khan A, Raza K. A coadunation of biological and mathematical perspectives on the pandemic COVID-19: a review. Coronaviruses. 2021;2(9):e030821190295. doi:10.20944/preprints202003.0214.v1
5. Yin Y, Wunderink RG. MERS, SARS and other coronaviruses as causes of pneumonia: MERS, SARS and coronaviruses. Respir. 2018;23(2):130-137. doi:10.1111/resp.13196
6. Chan-Yeung M, Xu R-H. SARS: epidemiology. Respirology. 2003;8(s1):S9-S14. doi:10.1046/j.1440-1843.2003.00518.x
7. Zaki AM, Van Boheemen S, Bestebroer TM, Osterhaus ADME, Fouchier RAM. Isolation of a novel coronavirus from a man with pneumonia in Saudi arabia. N Engl J Med. 2012;367(19):1814-1820. doi:10.1056/NEJMoa1211721
8. Zhou P, Yang X-L, Wang X-G, et al. A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature. 2020;579(7389):270-273. doi:10.1038/s41586-020-2951-z
9. Schoeman D, Fielding BC. Coronavirus envelope protein: current knowledge. Viral J. 2019;16(1):69. doi:10.1186/s12985-019-1182-0
10. Ashour HM, Ellkhairi WF, Rahman M, Elshabrawy HA. Insights into the recent 2019 novel coronavirus (SARS-CoV-2) in light of past human coronavirus outbreaks. Pathogens. 2020;9(3):186. doi:10.3390/pathogens9030186
11. Effekhari M, Enayati A, Doustmoqtadagh AH, Farzaci MH, Anevaj EY. Natural products in combination therapy for COVID-19: qT prolongation and urgent guidance. Nat Prod Commun. 2021;16(9):1-3. doi:10.1177/1934578X211032471
12. Xia S, Liu M, Wang C, et al. Inhibition of SARS-CoV-2 (previously 2019-nCoV) infection by a highly potent pan-coronavirus fusion inhibitor targeting its spike protein that harbors a high capacity to mediate membrane fusion. Cell Res. 2020;30(4):343-355. doi:10.1101/2020.03.09.983247
13. Masters PS. The molecular biology of coronaviruses. Adv Virus Res. 2006;66:193-292. doi:10.1016/S0065-3527(06)6005-3
14. Carlos WG, Dela Cruz CS, Cao B, Pasnick S, Jamil S. Novel wuhan (2019-nCoV) coronavirus. Am J Respir Crit Care Med. 2020;201(4):P7-P8. doi:10.1164/rccm.2014P7
15. Yeo C, Kaushal S, Yeo D. Enteric involvement of coronaviruses: is fecal–oral transmission of SARS-CoV-2 possible? Lancet Gastroenterol Hepatol. 2020;5(4):335-337. doi:10.1016/S2468-1253(20)30048-0
16. Agrawal PK, Agrawal C, Blunden G. Pharmacological significance of hesperidin and hesperetin, two citrus flavonoids as promising antiviral compound for prophylaxis against and combating COVID-19. Nat Prod Commun. 2021;16(10):1-15. doi:10.1177/1934578X211042540
17. Devi KP, Rajavel T, Nabavi SF, et al. Hesperidin: a promising anti-cancer agent from nature. Ind Crops Prod. 2015;76:582-589. doi:10.1016/j.indcrop.2015.07.051
18. Garg A, Garg S, Zaneveld LJ, Single AK. Chemistry and pharmacology of the citrus bioflavonoid hesperidin. Phytother Res. 2001;15(8):655-669. doi:10.1002/pr.1074
19. Monforte MT, Trovato A, Kirjavainen S, et al. Biological effects of hesperidin, a citrus flavonoid. (note II): hypolipidemic activity on experimental hypercholesterolemia in rat. Farmaco. 1995;50(9):595-599.
20. Galati EM, Monforte MT, Kirjavainen S, et al. Biological effects of hesperidin, a citrus flavonoid. (Note I): antinflammatory and analgesic activity. Farmaco. 1994;40(11):709-712.
21. Iskender H, Dokumacioglu E, Sen TM, Ince I, Kanbay Y, Saral S. The effect of hesperidin and quercetin on oxidative stress, NF-κB and SIRT1 levels in a STZ-induced experimental diabetes model. J Biomed Pharmacol. 2017;90:500-508. doi:10.1016/j.biopha.2017.03.012
22. Fu Z, Chen Z, Xie Q, Lei H, Xiang S. Hesperidin protects against IL-1β-induced inflammation in human osteoarthritis chondrocytes. Exp Ther Med. 2018;16(4):3721-3727. doi:10.3892/etm.2018.6616
23. Cheng I, Zheng W, Li M, et al. Citrus fruits are rich in flavonoids for immunoregulation and potential targeting ACE2. Nat Prod Bioprospect. 2020;12(1):4. doi:10.1007/s13659-022-00325-4
24. Wu C, Liu Y, Yang Y, et al. Analysis of therapeutic targets for SARS-CoV-2 and discovery of potential drugs by computational methods. Acta Pharmacologica Sinica B. 2020;10(5):766-781.
25. Utomo RY, Ikawati M, Meiyanto E. Revealing the potency of natural products in combination therapy for COVID-19: qT prolongation and urgent guidance. Heliyon. 2021;7(3):e06515. doi:10.1016/j.heliyon.2021.e06515
27. Dupuis J, Laurin P, Tardif JC, et al. Fourteen-days evolution of COVID-19 symptoms during the third wave in non-vaccinated subjects and effects of hesperidin therapy: a randomized, double-blinded placebo-controlled study. MedRxiv. 2021;1-29. doi:10.1101/2021.10.04.21264483

28. Pina ES, Coppedes JS, Contini SHT, et al. Improved production of quinone-methide triterpenoids by Chlorella ovogatun root cultures: possibilities for a non-destructive biotechnological process. Plant Cell Tiss Organ Cult. 2017;128(3):705-714.

29. Li J, Yan Y, Sun H, et al. Anticancer effects of pristimerin and the current through SARS-associated coronavirus 3a protein. Antiviral Res. 2015;20(6):1873-1876. doi:10.1016/j.antiviral.2011.09.097

30. Guo Y, Wang Y, Cao L, et al. A conserved inhibitory mechanism from oriental medicinal herbs inactivate Zika virus. Viruses. 2018;107:615-624. doi:10.1016/j.biopharm.2018.07.147

31. Schwarz S, Wang K, Yu W, Sun B, Schwarz W. Emodin inhibits viral replication and affects the host cell cycle environment. Acta Pharmacol Sin. 2017;38(3):392-401. doi:10.1038/aps.2016.110

32. Schwarz S, Wang K, Yu W, Sun B, Schwarz W. Emodin inhibits viral replication and affects the host cell cycle environment. Acta Pharmacol Sin. 2017;38(3):392-401. doi:10.1038/aps.2016.110

33. Wang J, Chen X, Wang W, et al. Glycyrrhizic acid as the antiviral component of Glycyrrhiza uralensis Fisch. against coxsackievirus A16 and enterovirus 71 of hand foot and mouth disease. J Ethnopharmacol. 2013;147(1):114-121. doi:10.1016/j.jep.2013.02.017

34. Abbassy MA, el-Gougary OA, el-Hamady S, Sholo MA. Insecticidal, acaricidal and synergistic effects of soosan, Panaxotum maritimum extracts and constituents. J Egypt Soc Parasitol. 1998;28(1):197-205.

35. Jin L, Ni B, Lin H, et al. Traditional usages, botany, phytochemistry, pharmacology and toxicology of Polygonum cuspidatum Thunb.: a review. Phytother Res. 2013;27(1):1041-1051. doi:10.1002/ptr.5631

36. Casu L, Cottiglia F, Leonti M, et al. Ungeremine effectively targets uNK2, a novel human uNK cell eukaryotic termination inhibitor? J Biol Chem. 2016;291(11):6907-6916. doi:10.1074/jbc.M115.705974

37. Jimenez A, Santos A, Alonso G, Vazquez D. Inhibitors of protein synthesis in eukaryotic cells. Biochimica et Biophysica Acta (BBA) - Nucleic Acids and Protein Synthesis. 1976;425(3):342-348. doi:10.1016/0005-2787(76)90261-6

38. Vrijens R, Vandeven Bergher DA, Vletterink AJ, Boeijé A. Lycorine: a eukaryotic termination inhibitor? J Biol Chem. 1986;261(2):505-507.

39. Lin L, Ni B, Lin H, et al. Traditional usages, botany, phytochemistry, pharmacology and toxicology of Polygonum cuspidatum Thunb.: a review. J Ethnopharmacol. 2013;159:158-183. doi:10.1016/j.ejphen.2014.11.009

40. Dong X, Fu J, Yin X, et al. Emodin: a review of its pharmacology, toxicology and pharmacokinetics. Physioblock. 2016;30(8):1207-1218. doi:10.1002/ptr.5631

41. Horvat M, Avbelj M, Durán-Alonso MB, et al. Anticancer therapies against enterovirus 71. Drug Discov. 2015;20(23-24):1041-1051. doi:10.1016/j.drudis.2010.10.008

42. Abbassy MA, el-Gougary OA, el-Hamady S, Sholo MA. Insecticidal, acaricidal and synergistic effects of soosan, Panaxotum maritimum extracts and constituents. J Egypt Soc Parasitol. 1998;28(1):197-205.
56. Matsumoto Y, Matsuura T, Aoyagi H, et al. Antiviral activity of glycyrrhizin against hepatitis C virus in vitro. Polyclay SJ, editor. PLoS ONE. 2013;8(7):e68992.

57. Li P, Zou H, Ren Y, Zarlenga DS, Ren X. Antiviral effect of diammonium glycyrrhizinate on cell infection by porcine parvovirus. Curr Microbiol. 2015;69(1):82-87. doi:10.1007/s00284-014-0540-9

58. Lin J-C, Cheng J-M, Hung M-S, et al. Inhibitory effects of some derivatives of glycyrrhizic acid against Epstein-Barr virus infection: structure−activity relationships. Antiviral Res. 2008;79(1):6-11. doi:10.1016/j.antiviral.2008.01.160

59. Hardy ME, Hendricks JM, Paulson JM, Faunce NR. 18β-Glycyrrhetinic acid inhibits rotavirus replication in culture. Virology. 2012;9(1):96. doi:10.1186/1743-422X-9-96

60. Wolkerstorfer A, Kurz H, Bachhofner N, Szolar OHJ. Glycyrrhizin inhibits influenza A virus uptake into the cell. Antiviral Res. 2009;83(2):171-178. doi:10.1016/j.antiviral.2009.04.012

61. Lida A B, Zarubaev VV, Baltina Lia A, et al. Glycyrrhizic acid derivatives as influenza A/H1N1 virus inhibitors. Biogy Med Chem Lett. 2015;25(8):1742-1746. doi:10.1016/j.bmcl.2015.02.074

62. Cinat J, Morgenstern B, Bauer G, Chandra P, Rabenau H, Doerr H. Glycyrrhizin, an acridic component of liquorice roots, and replication of SARS-associated coronavirus. Lancet. 2001;361(9374):2045-2046. doi:10.1016/s0140-6736(03)3615-x

63. Tsai J-C, Peng W-H, Chiu T-H, Lai S-C, Lee C-Y. Anti-inflammatory effects of Sophora dulcis L. and betulinic acid. Am J Chin Med. 2011;39(05):943-956. doi:10.1142/S0122018611009329

64. Yogeeswari P, Sirinam D. Betulinic acid and its derivatives: a review on their biological properties. CMC. 2005;12(6):657-666.

65. Thoe A, Masebe T, Suzuki Y, et al. Peltiphyrum africarium, a traditional South African medicinal plant, contains an anti HIV-1 constituent, betulinic acid. Tsubokaj Exp Med. 2009;217(2):93-99.

66. Fukda S. Betulinic acid: a natural product with anticancer activity. Mol Nutr Food Res. 2009;53(1):140-146.

67. Chowdhury AR, Mandal S, Mitra B, et al. Betulinic acid, a potent inhibitor of eukaryotic topoisomerase I: identification of the inhibitory step, the major functional group responsible and development of more potent derivatives. Med Sci Monit. 2002;8(7):BR254-BR265.

68. Haque S, Nawrot DA, Alakurtli S, et al. Screening and characterisation of antimicrobial properties of semisynthetic betulin derivatives. Panepinto J, editor. PLoS ONE. 2014;9(7):e102696.

69. Laavola M, Haavikko R, Hämäläinen M, et al. Betulin derivatives effectively suppress inflammation in vitro and in vivo. J Nat Prod. 2016;79(2):274-280.

70. Sousa MC, Varandas R, Santos RC, et al. Antileishmanial activity of semisynthetic lupane triterpenoids betulin and betulinic acid derivatives: synergistic effects with miltefosine. Cavalli A, editor. PLoS ONE. 2014;9(3):e89939.

71. Tang J, Jones SA, Jeffery JL, et al. Synthesis and biological evaluation of macrocyclized betulin derivatives as a novel class of anti-HIV-1 maturation inhibitors. The Open Med Chem J. 2014;8(1):23-27.

72. Pavlova NI, Savinova OV, Nikolaeva SN, et al. Antiviral activity of betulin, betulinic and betulonic acids against some enveloped and non-enveloped viruses. Fitoterapia. 2003;74(5):489-492.

73. Hong E-H, Song JH, Kang KB, et al. Anti-influenza activity of betulinic acid from Zizyphus jujuba on influenza A/PR/8 virus. Biomed Ther. 2015;23(4):345-349.

74. Kazakova OB, Giniyatullina GV, Yamansarov E, Tolstikov GA. Betulin and ursolic acid synthetic derivatives as inhibitors of Papilloma virus. Bioorganic Med Chem Lett. 2010;20(14):4088-4090.

75. Wen C-C, Kuo J-H, Jan J-T, et al. Specific plant terpenoids and lignoids possess potent antiviral activities against severe acute respiratory syndrome coronavirus. J Med Chem. 2007;50(17):4087-4095.

76. Zhang D, Wu K, Zhang X, Deng S, Peng B. In silico screening of Chinese herbal medicines with the potential to directly inhibit 2019 novel coronavirus. J Integr Med. 2020;18(2):152-158.

77. Van Dongen WD, Heck AJR. Binding of selected carbohydrates to apo-concanavalin A studied by electrospray ionization mass spectrometry. Analyst. 2000;125(4):583-589.

78. Carrington DM, Affret A, Hanke DE. Polypeptide ligation occurs during post-translational modification of concanavalin A. Nature. 1985;313(5997):64-67.

79. Mitchell CA, Ramessar K, O’Keefe BR. Antiviral lectins: selective inhibitors of viral entry. Antiviral Res. 2017;142:57-54.

80. Ahmed MN, Jahan R, Nissapatorn R, Rahmatullah M. Plant lectins as prospective antiviral biomolecules in the search for COVID-19 eradication strategies. Biomed Pharmacother. 2022;146:112507. doi:10.1016/j.biopha.2021.112507

81. Man M-Q, Yang B, Elias PM. Beneﬁts of hesperidin for cutaneous functions. Evid Based Complement Alternat Med. 2019:1-19. doi:10.1155/2019/2676307.

82. Elfwal MA, Towler MJ, Reich NG, et al. Dried whole plant Artemisia annua as an antimalarial therapy. Snounou G, editor. PLoS ONE. 2012;7(12):e52746.

83. Agrawal PK, Agrawal C, Blunden G. Artemisia extracts and artemisinin-based antimalarials for COVID-19 management: could these be effective antivirals for COVID-19 treatment? Molecules. 2022;27(12):3828.

84. Li G, Yuan M, Li H, et al. Safety and efficacy of artemisinin-piperaquine for treatment of COVID-19: an open-label, non-randomised and controlled trial. Int J Antimicrob Agents. 2021;57(1):106216. doi:10.1016/j.ijantimicag.2020.106216

85. Yang Y, Islam MS, Wang J, Li Y, Chen X. Traditional Chinese medicine in the treatment of patients infected with 2019-novel coronavirus (SARS-CoV-2): a review and perspective. Int J Biol Sci. 2020;16(10):1708-1717.

86. Fu Y-J, Yan Y-Q, Qin H-Q, et al. Effects of different principles of Traditional Chinese Medicine treatment on TLR7/NF-κB signaling pathway in in vitro and in vivo. Curr Microbiol. 2018;76(1):158.

87. Gao J, Li J, Shao X, et al. Antiinflammatory and immunoregulatory effects of total glucosides of Yufingfeng powder. Chin Med J. 2020;133(1):1-16.

88. Gao J, Li J, Shao X, et al. The Chinese prescription Lianhuaqingwen capsule exerts anti-influenza activity through
the inhibition of viral propagation and impacts immune function. 
*BMC Complement Altern Med.* 2017;17(1):130.

89. Yan Z. Randomized controlled trial assessing the efficacy of Lianhua Qingwen as an adjuvant treatment in patient with mild symptoms of Covid-19. https://clinicaltrials.gov/ct2/show/NCT04433013

90. Shen L, Niu J, Wang C, et al. High throughput screening and identification of potent broad-spectrum inhibitors of coronaviruses. *Gallagher T*, editor. *J Virol.* 2019;93(12):e0023-19.

91. Lau K-M, Lee K-M, Koon C-M, et al. Immunomodulatory and anti-SARS activities of *Houttuynia cordata*. *J Ethnopharmacol.* 2008;118(1):79-85.

92. Kim DE, Min JS, Jang MS, et al. Natural bis-benzylisoquinoline alkaloids-tetrandrine, fangchinoline, and cepharanthine, inhibit human coronavirus OC43 infection of MRC-5 human lung cells. *Biomolecules*. 2019;9(11):696. doi:10.3390/biom9110696